Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 2

Completed

• Conditions: Non-Cystic Fibrosis Bronchiectasis
• Interventions: Drug: Brensocatib 25 mg; Drug: Placebo; Drug: Brensocatib 10 mg

• Registration Number: NCT03218917
• Lead Sponsor: Insmed Incorporated

Brief Summary

The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.

Detailed Description

Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter, multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics (PK) of INS1007 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (NCFBE).

Study Timeline

• Study First Submitted: 2017-07-11
• Study First Submitted QC: 2017-07-12
• Study First Posted: 2017-07-17
• Study Start: 2017-10-31
• Primary Completion: 2019-12-12
• Study Completion: 2019-12-12
• Disposition First Submitted: 2020-12-11
• Results First Submitted: 2022-12-09
• Results First Submitted QC: 2023-01-16
• Disposition First Submitted QC: 2023-01-16
• Results First Posted: 2023-02-08
• Disposition First Posted: 2023-02-08
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-23
• Last Update Posted: 2023-03-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 256

Inclusion Criteria

1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or recurrent respiratory infections)
2. Are current sputum producers with a history of chronic expectoration and able to provide a sputum sample during Screening
3. Have at least 2 documented pulmonary exacerbations in the past 12 months before Screening

Exclusion Criteria

1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma
2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency
3. Are current smokers
4. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis
5. Have any acute infections, (including respiratory infections)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Brensocatib 25 mg	Brensocatib 25 mg	Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
Placebo	Placebo	Participants received the matching placebo QD before breakfast, for 24 weeks.
Brensocatib 10 mg	Brensocatib 10 mg	Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.

Primary Outcome Measures

Name	Time	Method
Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period	Baseline (Day 1) to Week 24	Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.

Secondary Outcome Measures

Name	Time	Method
Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period	Screening (Days -42 to -1) to Week 24	FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath. The percent predicted FEV1 was calculated by converting the spirometer reading to a percentage of what would be predicted as normal FEV1 based on a several personal factors (e.g. sex, age, etc.). Change from screening in percent predicted FEV1 to Week 24 was calculated as: percent predicted FEV1 value at Week 24 and percent predicted FEV1 value at screening. A positive percent change from screening indicates an improvement in lung function. The analysis was done using analysis of covariance (ANCOVA) with Pa colonization status and maintenance macrolide antibiotic use at Baseline as covariates.
Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period	Baseline (Day 1) to Week 24	The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. The analysis was based on mixed model for repeated measures (MMRM) approach.
Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum	Baseline (Day 1) to Week 24	The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration and on-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.
Number of Participants Who Experienced a Pulmonary Exacerbation	Baseline (Day 1) to Week 24	Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics. 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation.

Trial Locations

Locations (108)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Phoenix Medical Group; 🇺🇸 Peoria, Arizona, United States

NewportNativeMD; 🇺🇸 Newport Beach, California, United States

Palmtree Clinical Research; 🇺🇸 Palm Springs, California, United States

UC Davis Medical Center; 🇺🇸 Sacramento, California, United States

Stanford University Medical Center; 🇺🇸 Stanford, California, United States

National Jewish Heath; 🇺🇸 Denver, Colorado, United States

UConn Health Center; 🇺🇸 Farmington, Connecticut, United States

MedStar Georgetown University Hospital; 🇺🇸 Washington, District of Columbia, United States

Clinical Research Specialists, LLC; 🇺🇸 Celebration, Florida, United States

Scroll for more (98 remaining)